A summit attended by healthcare experts and representatives from the National Institutes of Health (NIH), American Cancer Society, the American Society for Cancer Research (ASCR), and American Society of Clinical Oncology (ASCO) convened, producing a list of recommendations to extend better cancer screening and care to currently underserved minority populations. Among the recommendations is to include minority health care teams in clinical trial design; include sustainability plans for maintaining community relationships; and ensure that major cancer initiatives include sufficient representation from minority populations. The hope is that through these recommendations, screening and treatment can benefit all populations, regardless of race, ethnicity or economic status. http://bit.ly/2vsJhNn
- What is expanded access and how can a desperately ill patient find treatment through this process? Are there online tools available for navigating the steps needed?
- How many drugs provided through expanded access actually get marketing approval from the FDA?
- Leading cancer organizations have formed a coalition and provided recommendations to extend better care to minorities. What do they suggest?
- The Reagan-Udall Foundation Navigator: An Online Tool to Help Desperately Ill Patients Considering Compassionate Use Treatment Options
- Diversity in Clinical Trials—History and Barriers